leflunomide has been researched along with Aortitis Syndrome in 13 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the efficacy and safety of leflunomide (LEF) versus tofacitinib (TOF) in Takayasu arteritis (TAK) patients." | 8.12 | Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study. ( Chen, H; Dai, X; Ding, Z; Ji, Z; Jiang, L; Jin, X; Kong, X; Ma, L; Wang, J; Wu, S, 2022) |
| "To evaluate the efficacy and safety of leflunomide (LEF) as induction treatment in a series of Takayasu arteritis (TA) patients based on a Chinese cohort." | 7.96 | Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. ( Cui, X; Dai, X; Ding, J; Dong, Z; Feng, X; Fu, W; Jiang, L; Li, S; Lin, H; Lin, J; Lu, Y; Lv, P; Ma, L; Sun, X; Tan, W; Wang, C; Wang, L; Wang, Y; Wu, M; Wu, R; Yang, C; Zhang, L; Zhang, Z; Zhou, Z; Zou, Y, 2020) |
| "To evaluate the efficacy of leflunomide in controlling disease activity in patients with Takayasu arteritis (TA) refractory or intolerant to conventional treatment." | 7.78 | Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. ( da Silva, MD; de Souza, AW; Machado, LS; Oliveira, AC; Pinheiro, FA; Sato, EI, 2012) |
| " This report aims to assess the effectiveness and safety of leflunomide (LEF) in Takayasu arteritis (TA) and giant cell arteritis (GCA)." | 5.41 | Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies. ( Brugarolas, E; Estrada, P; LLop, D; Maymó-Paituvi, P; Narváez, J; Nolla, JM; Palacios-Olid, J; Vidal-Montal, P, 2023) |
| " Results of in-vitro studies on Janus kinase (JAK)/signal transducers and activators of transcription and mammalian target of rapamycin (mTOR) pathways, comparative studies with leflunomide as an induction therapy, and a long-term follow-up study with tocilizumab may contribute to the management of Takayasu arteritis." | 5.12 | Aortitis: an update. ( Erdogan, M, 2021) |
| "To investigate the efficacy and safety of leflunomide (LEF) versus tofacitinib (TOF) in Takayasu arteritis (TAK) patients." | 4.12 | Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study. ( Chen, H; Dai, X; Ding, Z; Ji, Z; Jiang, L; Jin, X; Kong, X; Ma, L; Wang, J; Wu, S, 2022) |
| "To evaluate the efficacy and safety of leflunomide (LEF) as induction treatment in a series of Takayasu arteritis (TA) patients based on a Chinese cohort." | 3.96 | Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. ( Cui, X; Dai, X; Ding, J; Dong, Z; Feng, X; Fu, W; Jiang, L; Li, S; Lin, H; Lin, J; Lu, Y; Lv, P; Ma, L; Sun, X; Tan, W; Wang, C; Wang, L; Wang, Y; Wu, M; Wu, R; Yang, C; Zhang, L; Zhang, Z; Zhou, Z; Zou, Y, 2020) |
| "To evaluate the efficacy of leflunomide in controlling disease activity in patients with Takayasu arteritis (TA) refractory or intolerant to conventional treatment." | 3.78 | Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. ( da Silva, MD; de Souza, AW; Machado, LS; Oliveira, AC; Pinheiro, FA; Sato, EI, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 7 (53.85) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J | 2 |
| Dai, X | 3 |
| Ma, L | 5 |
| Wu, S | 2 |
| Jin, X | 1 |
| Ji, Z | 2 |
| Chen, H | 2 |
| Ding, Z | 1 |
| Jiang, L | 3 |
| Kong, X | 2 |
| Sun, Y | 1 |
| Hou, J | 1 |
| Wang, L | 2 |
| Gong, Y | 1 |
| Sun, X | 2 |
| Narváez, J | 1 |
| Estrada, P | 1 |
| LLop, D | 1 |
| Vidal-Montal, P | 1 |
| Brugarolas, E | 1 |
| Maymó-Paituvi, P | 1 |
| Palacios-Olid, J | 1 |
| Nolla, JM | 1 |
| Sebastian, A | 2 |
| Kayani, A | 2 |
| Dasgupta, B | 2 |
| Erdogan, M | 1 |
| Tomelleri, A | 1 |
| Coath, F | 1 |
| Prieto-Pena, D | 1 |
| Mo, J | 1 |
| Keser, G | 1 |
| Aksu, K | 1 |
| Direskeneli, H | 3 |
| Machado, LSG | 1 |
| Oliveira, ACD | 1 |
| Semedo-Kuriki, P | 1 |
| de Souza, AWS | 1 |
| Sato, EI | 2 |
| Cui, X | 1 |
| Yang, C | 1 |
| Tan, W | 1 |
| Zhang, L | 1 |
| Zhang, Z | 1 |
| Feng, X | 1 |
| Wu, R | 1 |
| Zou, Y | 1 |
| Zhou, Z | 1 |
| Lu, Y | 1 |
| Wang, Y | 1 |
| Wu, M | 1 |
| Li, S | 1 |
| Lin, H | 1 |
| Dong, Z | 1 |
| Fu, W | 1 |
| Wang, C | 1 |
| Ding, J | 1 |
| Lv, P | 1 |
| Lin, J | 1 |
| Alibaz-Oner, F | 2 |
| de Souza, AW | 1 |
| da Silva, MD | 1 |
| Machado, LS | 1 |
| Oliveira, AC | 1 |
| Pinheiro, FA | 1 |
| Unizony, S | 1 |
| Stone, JH | 1 |
| Stone, JR | 1 |
| Aydin, SZ | 1 |
6 reviews available for leflunomide and Aortitis Syndrome
| Article | Year |
|---|---|
Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies.
Topics: Antirheumatic Agents; Cohort Studies; Giant Cell Arteritis; Glucocorticoids; Humans; Leflunomide; Me | 2023 |
Aortitis: an update.
Topics: Antibodies, Monoclonal, Humanized; Aorta; Aortitis; Female; Follow-Up Studies; Giant Cell Arteritis; | 2021 |
Takayasu arteritis: an update
Topics: Antibodies, Monoclonal, Humanized; Biomarkers; Endovascular Procedures; Guidelines as Topic; Humans; | 2018 |
Update on Takayasu's arteritis.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Humanized; Biological Products; Biomarkers; Diagnos | 2015 |
New treatment strategies in large-vessel vasculitis.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Arteritis; Giant Cell Art | 2013 |
Advances in the diagnosis, assessment and outcome of Takayasu's arteritis.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Fluorodeoxyglucose F18; Humans; Isoxazoles; | 2013 |
7 other studies available for leflunomide and Aortitis Syndrome
| Article | Year |
|---|---|
Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study.
Topics: Glucocorticoids; Humans; Immunosuppressive Agents; Leflunomide; Piperidines; Prospective Studies; Py | 2022 |
A novel molecular mechanism of vascular fibrosis in Takayasu arteritis: macrophage-derived GPNMB promoting adventitial fibroblast extracellular matrix production in the aorta.
Topics: Adventitia; Aorta; Extracellular Matrix; Fibroblasts; Fibrosis; Humans; Leflunomide; Macrophages; Me | 2023 |
Excellent Response to Leflunomide in a Case of Large-Vessel Giant Cell Arteritis Demonstrated Simultaneously by Clinical, Laboratory, Ultrasound, and Positron Emission Tomography/Computed Tomography Parameters.
Topics: Aged; Female; Fluorodeoxyglucose F18; Giant Cell Arteritis; Humans; Laboratories; Leflunomide; Posit | 2021 |
Long-Term Efficacy and Safety of Leflunomide in Large-Vessel Giant Cell Arteritis: A Single-Center, 10-Year Experience.
Topics: Giant Cell Arteritis; Humans; Leflunomide; Takayasu Arteritis | 2022 |
Endothelial progenitor cells and vascular endothelial growth factor in patients with Takayasu's arteritis.
Topics: Adult; Anti-Inflammatory Agents; Brazil; Case-Control Studies; Cell Count; Cross-Sectional Studies; | 2018 |
Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort.
Topics: Adolescent; Adult; China; Cyclophosphamide; Disease Progression; Female; Humans; Immunosuppressive A | 2020 |
Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study.
Topics: Adult; Blood Sedimentation; C-Reactive Protein; Drug Therapy, Combination; Female; Follow-Up Studies | 2012 |